By Fineline Cube Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that it has signed an exclusive licensing agreement with US‑based Sentivera Therapeutics, Inc. (formerly RespiveraHealths, Inc.), granting Sentivera exclusive rights to develop, manufacture, and commercialise a preclinical autoimmune asset worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan. The deal delivers approximately USD 75.89 million in upfront consideration — including a 17.5% equity stake in Sentivera — plus up to USD 1.46 billion in milestone payments and royalties.
Deal Terms
| Item | Detail |
|---|---|
| Licensor | Haisco (SHE: 002653) |
| Licensee | Sentivera Therapeutics, Inc. (Delaware, US) |
| Asset | Preclinical oral small‑molecule autoimmune/inflammatory disease candidate |
| Territory | Worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan |
| Upfront Payment | ~USD 75.89M (USD 40M cash + 11,964,016 Sentivera shares worth ~USD 35.89M) |
| Equity Stake | 17.5% of Sentivera |
| Milestones & Royalties | Up to USD 1.46B, plus share of sublicensing revenue |
Asset Profile
- Molecule: Oral small‑molecule formulation, independently developed by Haisco with proprietary intellectual property
- Indication Area: Inflammatory and autoimmune diseases
- Preclinical Data: Significant efficacy and activity demonstrated in relevant animal models
- Mechanism of Action: Clear and well‑defined, supporting differentiation within the autoimmune pipeline
Strategic Rationale
- Deal Structure: The combination of cash, equity, and milestone payments aligns Haisco’s upside with Sentivera’s long‑term value creation, while the sublicensing revenue share captures additional value from future partnering.
- Partner Backing: Sentivera, incorporated in Delaware on 25 Nov 2025, is founded and backed by Population Health Partners, L.P. (PHP), providing institutional capital and strategic support for clinical development.
- Global Expansion: The transaction marks another step in Haisco’s strategy to monetise its proprietary pipeline through international out‑licensing while retaining Greater China rights.
Market Impact & Outlook
- Total Potential Value: Up to approximately USD 1.54 billion (upfront plus milestones), positioning the transaction among the larger China‑origin autoimmune licensing deals at the preclinical stage.
- Investor Signal: The sizeable equity component (17.5% stake) gives Haisco shareholders direct exposure to the asset’s future appreciation through Sentivera.
- Sector Context: Global demand for oral autoimmune therapies remains strong as payers and developers seek convenient alternatives to biologics.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding development milestones, commercialisation prospects, and financial expectations for the licensed asset. Actual results may differ due to risks including preclinical‑to‑clinical translation, regulatory outcomes, and partnering dynamics.-Fineline Info & Tech